Immunogenicity and protective efficacy of recombinant proteins consisting of multiple epitopes of foot-and-mouth disease virus fused with flagellin
- 136 Downloads
Many recent studies have shown that flagellin fused to heterologous antigens can induce significantly enhanced humoral and cellular immune responses through its adjuvant activity. Therefore, in this study, two key B cell epitopes and a truncated VP1 (ΔVP1) protein from foot-and-mouth disease virus (FMDV) were expressed as flagellin fusion proteins in different patterns. Specifically, ΔVP1 and two duplicates of two key B cell epitopes (2×B1B2) were fused separately to the C-terminus of flagellin with a universal exogenous T cell epitope to construct FT (Flagellin-Truncated VP1) and FME (Flagellin-Multiple Epitopes). In addition, the D3 domain of flagellin was replaced by ΔVP1 in FME, yielding FTME (Flagellin-Truncated VP1-Multiple Epitopes). The immunogenicity and protective efficacy of the three fusion proteins as novel FMDV vaccine candidates were evaluated. The results showed that FT, FME, and FTME elicited significant FMDV-specific IgG responses at 10 μg/dose compared with the mock group (P < 0.05), with FTME producing the highest response. No significant differences in the antibody response to FTME were observed between different immunization routes or among adjuvants (ISA-206, poly(I·C), MPLA, and CpG-ODN) in mice. In addition, at 30 μg/dose, all three fusion proteins significantly induced neutralizing antibody production and upregulated the levels of some cytokines, including TNF-α, IFN-γ, and IL-12, in guinea pigs. Importantly, all three fusion proteins provided effective protective immunity against FMDV challenge in guinea pigs, though different protection rates were found. The results presented in this study indicate that the FTME fusion protein is a promising novel vaccine candidate for the future prevention and control of foot-and-mouth disease.
KeywordsFMDV Epitope Flagellin Recombinant fusion Vaccine
This study was supported by the National Key Research and Development Program (2016YFD0501505), the Agriculture Research System of China (CARS-35), the Central Public Interest Scientific Institution Basal Research Fund (Y2016CG23), and the National Natural Science Foundation of China (31602095).
Compliance with ethical standards
Conflict of interests
The authors declare that they have no conflict of interest.
All guinea pig experiments were performed in a biosafety level 3 laboratory at the Lanzhou Veterinary Research Institute (LVRI) at the Chinese Academy of Agricultural Sciences (CAAS). This study was approved by the Institutional Animal Use and Care Committee of the CAAS. All guinea pigs used in the present study were humanely bred during the experiments and were euthanized at the end of the study.
- Bargieri DY, Rosa DS, Braga CJ, Carvalho BO, Costa FT, Espindola NM, Vaz AJ, Soares IS, Ferreira LC, Rodrigues MM (2008) New malaria vaccine candidates based on the Plasmodium vivax merozoite surface protein-1 and the TLR-5 agonist Salmonella Typhimurium FliC flagellin. Vaccine 26(48):6132–6142. https://doi.org/10.1016/j.vaccine.2008.08.070 CrossRefGoogle Scholar
- Capozzo AV, Wilda M, Bucafusco D, de Los ALM, Franco-Mahecha OL, Mansilla FC, Perez-Filgueira DM, Grigera PR (2011) Vesicular stomatitis virus glycoprotein G carrying a tandem dimer of foot and mouth disease virus antigenic site a can be used as DNA and peptide vaccine for cattle. Antivir Res 92(2):219–227. https://doi.org/10.1016/j.antiviral.2011.08.006 CrossRefGoogle Scholar
- Chen YS, Hung YC, Lin WH, Huang GS (2010) Assessment of gold nanoparticles as a size-dependent vaccine carrier for enhancing the antibody response against synthetic foot-and-mouth disease virus peptide. Nanotechnology 21(19):195101. https://doi.org/10.1088/0957-4484/21/19/195101 CrossRefGoogle Scholar
- Dicara D, Burman A, Clark S, Berryman S, Howard MJ, Hart IR, Marshall JF, Jackson T (2008) Foot-and-mouth disease virus forms a highly stable, EDTA-resistant complex with its principal receptor, integrin alphavbeta6: implications for infectiousness. J Virol 82(3):1537–1546. https://doi.org/10.1128/JVI.01480-07 CrossRefGoogle Scholar
- Doel TR, Gale C, Do AC, Mulcahy G, Dimarchi R (1990) Heterotypic protection induced by synthetic peptides corresponding to three serotypes of foot-and-mouth disease virus. J Virol 64(5):2260–2264Google Scholar
- Du Y, Li Y, He H, Qi J, Jiang W, Wang X, Tang B, Cao J, Wang X, Jiang P (2008) Enhanced immunogenicity of multiple-epitopes of foot-and-mouth disease virus fused with porcine interferon alpha in mice and protective efficacy in guinea pigs and swine. J Virol Methods 149(1):144–152. https://doi.org/10.1016/j.jviromet.2007.12.018 CrossRefGoogle Scholar
- Golde WT, Pacheco JM, Duque H, Doel T, Penfold B, Ferman GS, Gregg DR, Rodriguez LL (2005) Vaccination against foot-and-mouth disease virus confers complete clinical protection in 7 days and partial protection in 4 days: use in emergency outbreak response. Vaccine 23(50):5775–5782. https://doi.org/10.1016/j.vaccine.2005.07.043 CrossRefGoogle Scholar
- Huleatt JW, Jacobs AR, Tang J, Desai P, Kopp EB, Huang Y, Song L, Nakaar V, Powell TJ (2007) Vaccination with recombinant fusion proteins incorporating Toll-like receptor ligands induces rapid cellular and humoral immunity. Vaccine 25(4):763–775. https://doi.org/10.1016/j.vaccine.2006.08.013 CrossRefGoogle Scholar
- Huleatt JW, Nakaar V, Desai P, Huang Y, Hewitt D, Jacobs A, Tang J, McDonald W, Song L, Evans RK, Umlauf S, Tussey L, Powell TJ (2008) Potent immunogenicity and efficacy of a universal influenza vaccine candidate comprising a recombinant fusion protein linking influenza M2e to the TLR5 ligand flagellin. Vaccine 26(2):201–214. https://doi.org/10.1016/j.vaccine.2007.10.062 CrossRefGoogle Scholar
- Lawrence P, Pacheco JM, Uddowla S, Hollister J, Kotecha A, Fry E, Rieder E (2013) Foot-and-mouth disease virus (FMDV) with a stable FLAG epitope in the VP1 G-H loop as a new tool for studying FMDV pathogenesis. Virology 436(1):150–161. https://doi.org/10.1016/j.virol.2012.11.001 CrossRefGoogle Scholar
- Li G, Chen W, Yan W, Zhao K, Liu M, Zhang J, Fei L, Xu Q, Sheng Z, Lu Y, Zheng Z (2004) Comparison of immune responses against foot-and-mouth disease virus induced by fusion proteins using the swine IgG heavy chain constant region or beta-galactosidase as a carrier of immunogenic epitopes. Virology 328(2):274–281. https://doi.org/10.1016/j.virol.2004.07.025 CrossRefGoogle Scholar
- Li K, Bao H, Wei G, Li D, Chen Y, Fu Y, Cao Y, Li P, Sun P, Bai X, Ma X, Zhang J, Lu Z, Liu Z (2017) Molecular vaccine prepared by fusion of XCL1 to the multi-epitope protein of foot-and-mouth disease virus enhances the specific humoural immune response in cattle. Appl Microbiol Biotechnol 101(21):7889–7900. https://doi.org/10.1007/s00253-017-8523-y CrossRefGoogle Scholar
- Liu X, Fang Y, Zhou P, Lu Y, Zhang Q, Xiao S, Dong Z, Pan L, Lv J, Zhang Z, Zhang Y, Wang Y (2017) Chimeric virus-like particles elicit protective immunity against serotype O foot-and-mouth disease virus in guinea pigs. Appl Microbiol Biotechnol 101(12):4905–4914. https://doi.org/10.1007/s00253-017-8246-0 CrossRefGoogle Scholar
- McDonald WF, Huleatt JW, Foellmer HG, Hewitt D, Tang J, Desai P, Price A, Jacobs A, Takahashi VN, Huang Y, Nakaar V, Alexopoulou L, Fikrig E, Powell TJ (2007) A West Nile virus recombinant protein vaccine that coactivates innate and adaptive immunity. J Infect Dis 195(11):1607–1617. https://doi.org/10.1086/517613 CrossRefGoogle Scholar
- Morgan DO, Moore DM (1990) Protection of cattle and swine against foot-and-mouth disease, using biosynthetic peptide vaccines. Am J Vet Res 51(1):40–45Google Scholar
- Song L, Nakaar V, Kavita U, Price A, Huleatt J, Tang J, Jacobs A, Liu G, Huang Y, Desai P, Maksymiuk G, Takahashi V, Umlauf S, Reiserova L, Bell R, Li H, Zhang Y, McDonald WF, Powell TJ, Tussey L (2008) Efficacious recombinant influenza vaccines produced by high yield bacterial expression: a solution to global pandemic and seasonal needs. PLoS One 3(5):e2257. https://doi.org/10.1371/journal.pone.0002257 CrossRefGoogle Scholar
- Taylor DN, Treanor JJ, Sheldon EA, Johnson C, Umlauf S, Song L, Kavita U, Liu G, Tussey L, Ozer K, Hofstaetter T, Shaw A (2012) Development of VAX128, a recombinant hemagglutinin (HA) influenza-flagellin fusion vaccine with improved safety and immune response. Vaccine 30(39):5761–5769. https://doi.org/10.1016/j.vaccine.2012.06.086 CrossRefGoogle Scholar
- Wang G, Pan L, Zhang Y, Wang Y, Zhang Z, Lu J, Zhou P, Fang Y, Jiang S (2011) Intranasal delivery of cationic PLGA nano/microparticles-loaded FMDV DNA vaccine encoding IL-6 elicited protective immunity against FMDV challenge. PLoS One 6(11):e27605. https://doi.org/10.1371/journal.pone.0027605 CrossRefGoogle Scholar
- Wen X, Wen K, Cao D, Li G, Jones RW, Li J, Szu S, Hoshino Y, Yuan L (2014) Inclusion of a universal tetanus toxoid CD4(+) T cell epitope P2 significantly enhanced the immunogenicity of recombinant rotavirus DeltaVP8* subunit parenteral vaccines. Vaccine 32(35):4420–4427. https://doi.org/10.1016/j.vaccine.2014.06.060 CrossRefGoogle Scholar
- Zamorano P, Wigdorovitz A, Perez-Filgueira M, Carrillo C, Escribano JM, Sadir AM, Borca MV (1995) A 10-amino-acid linear sequence of VP1 of foot and mouth disease virus containing B- and T-cell epitopes induces protection in mice. Virology 212(2):614–621. https://doi.org/10.1006/viro.1995.1519 CrossRefGoogle Scholar